Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VXM 01

Next Previous
Search
Drug Profile

VXM 01

Alternative Names: VEGFR2 peptide vaccine - VAXIMM; VEGFR2 specific T cell vaccine; VXM-01

Latest Information Update: 30 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck KGaA
  • Developer Merck KGaA; Pfizer; VAXIMM
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Peptide vaccines
  • Mechanism of Action Bacteria replacements; Immunostimulants; Vascular endothelial growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma
  • No development reported Colorectal cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 30 Dec 2022 Phase-I/II clinical trial is ongoing in Glioblastoma (Combination therapy, Second-line therapy or greater) in France and Netherlands (PO) (NCT03750071)
  • 29 May 2020 Efficacy and adverse events data from a phase I/II trial in Glioblastoma presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
  • 28 Jun 2019 No recent reports of development identified for phase-I development in Glioblastoma(Late-stage disease, Recurrent, Second-line therapy or greater) in Germany (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top